Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Biotechnology and Pharma:  Evolution and Adaptation

Biotechnology and Pharma: Evolution and Adaptation

Tuesday, October 7, 2008

The New York Academy of Sciences

Presented By

Presented by Science Alliance , Columbia University Biotechnology Association and New York University Biotechnology Association

 

 

Moderator: Andrew Marshall, Editor, Nature Biotechnology; Speakers: Ralph Marcello, Senior Manager, Deloitte Consulting LLP; Alan E. Smith, EVP and CSO, Genzyme; Robert A. Copeland, EVP and CSO, EpiZyme, Inc.; Cole Werble, Editor-in-Chief, The RPM Report (Windhover Information, Inc.); Peter Vaccari, Orphan Products Program, FDA; Barbara Mittleman, Office of Science Policy Analysis, NIH

Pharma and biotech provides us medicines and treatments that improve our lives, but these industries face significant challenges of decreased innovation and dwindling drug pipelines. Join us for an expert panel discussion that will address the impact of science, regulation, business and society on the current state of drug development and its designs for the future.